ZA200305764B - A method for identification, isolation and production of antigens to a specific pathogen. - Google Patents
A method for identification, isolation and production of antigens to a specific pathogen. Download PDFInfo
- Publication number
- ZA200305764B ZA200305764B ZA200305764A ZA200305764A ZA200305764B ZA 200305764 B ZA200305764 B ZA 200305764B ZA 200305764 A ZA200305764 A ZA 200305764A ZA 200305764 A ZA200305764 A ZA 200305764A ZA 200305764 B ZA200305764 B ZA 200305764B
- Authority
- ZA
- South Africa
- Prior art keywords
- seq
- antigens
- hyperimmune serum
- pathogen
- reactive
- Prior art date
Links
- 108091007433 antigens Proteins 0.000 title claims description 212
- 102000036639 antigens Human genes 0.000 title claims description 212
- 239000000427 antigen Substances 0.000 title claims description 211
- 244000052769 pathogen Species 0.000 title claims description 96
- 230000001717 pathogenic effect Effects 0.000 title claims description 87
- 238000000034 method Methods 0.000 title claims description 84
- 238000004519 manufacturing process Methods 0.000 title claims description 27
- 238000002955 isolation Methods 0.000 title claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 92
- 238000002360 preparation method Methods 0.000 claims description 91
- 230000000521 hyperimmunizing effect Effects 0.000 claims description 89
- 210000002966 serum Anatomy 0.000 claims description 86
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 71
- 239000012634 fragment Substances 0.000 claims description 70
- 230000002163 immunogen Effects 0.000 claims description 61
- 241000282414 Homo sapiens Species 0.000 claims description 57
- 230000014509 gene expression Effects 0.000 claims description 56
- 238000012216 screening Methods 0.000 claims description 54
- 230000000890 antigenic effect Effects 0.000 claims description 50
- 229960005486 vaccine Drugs 0.000 claims description 50
- 230000009257 reactivity Effects 0.000 claims description 45
- 230000001580 bacterial effect Effects 0.000 claims description 39
- 208000015181 infectious disease Diseases 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 22
- 241000191967 Staphylococcus aureus Species 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 20
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 18
- 108010026552 Proteome Proteins 0.000 claims description 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 230000028993 immune response Effects 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 13
- 210000002421 cell wall Anatomy 0.000 claims description 13
- 238000010367 cloning Methods 0.000 claims description 12
- 230000003308 immunostimulating effect Effects 0.000 claims description 12
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 210000003705 ribosome Anatomy 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000006166 lysate Substances 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 7
- 241000191940 Staphylococcus Species 0.000 claims description 6
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 210000000952 spleen Anatomy 0.000 claims description 6
- 210000004989 spleen cell Anatomy 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 5
- 238000010188 recombinant method Methods 0.000 claims description 5
- 241000711549 Hepacivirus C Species 0.000 claims description 4
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 claims description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 241000193738 Bacillus anthracis Species 0.000 claims description 3
- 208000034309 Bacterial disease carrier Diseases 0.000 claims description 3
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 3
- 241001647372 Chlamydia pneumoniae Species 0.000 claims description 3
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 3
- 241000194032 Enterococcus faecalis Species 0.000 claims description 3
- 241000709721 Hepatovirus A Species 0.000 claims description 3
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 3
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 3
- 239000000854 Human Growth Hormone Substances 0.000 claims description 3
- 241000186362 Mycobacterium leprae Species 0.000 claims description 3
- 241000702670 Rotavirus Species 0.000 claims description 3
- 241000714474 Rous sarcoma virus Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 241000607626 Vibrio cholerae Species 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 244000052613 viral pathogen Species 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241000228257 Aspergillus sp. Species 0.000 claims description 2
- 241000222122 Candida albicans Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 241001442539 Plasmodium sp. Species 0.000 claims description 2
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 229940065181 bacillus anthracis Drugs 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 2
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 244000053095 fungal pathogen Species 0.000 claims description 2
- 230000002147 killing effect Effects 0.000 claims description 2
- 229920002851 polycationic polymer Polymers 0.000 claims description 2
- 244000079416 protozoan pathogen Species 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 229940118696 vibrio cholerae Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 239000000813 peptide hormone Substances 0.000 claims 1
- 229940030998 streptococcus agalactiae Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 189
- 102000004169 proteins and genes Human genes 0.000 description 173
- 235000018102 proteins Nutrition 0.000 description 171
- 108700026244 Open Reading Frames Proteins 0.000 description 68
- 108020004414 DNA Proteins 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 56
- 230000006870 function Effects 0.000 description 41
- 235000001014 amino acid Nutrition 0.000 description 25
- 235000019687 Lamb Nutrition 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 18
- 102000018697 Membrane Proteins Human genes 0.000 description 18
- 108010052285 Membrane Proteins Proteins 0.000 description 18
- 241000295644 Staphylococcaceae Species 0.000 description 18
- 230000027455 binding Effects 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 238000002702 ribosome display Methods 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 14
- 101150012518 lamB gene Proteins 0.000 description 14
- 210000004379 membrane Anatomy 0.000 description 14
- 101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 description 13
- 101100398653 Yersinia pestis lamB1 gene Proteins 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 238000002255 vaccination Methods 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000000306 component Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 108010007004 cathelin Proteins 0.000 description 9
- 210000005007 innate immune system Anatomy 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 229930027917 kanamycin Natural products 0.000 description 9
- 229960000318 kanamycin Drugs 0.000 description 9
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 9
- 229930182823 kanamycin A Natural products 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 108010078791 Carrier Proteins Proteins 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000014207 opsonization Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 101100390711 Escherichia coli (strain K12) fhuA gene Proteins 0.000 description 7
- 108010013639 Peptidoglycan Proteins 0.000 description 7
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000405 serological effect Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 6
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 6
- 102100024407 Jouberin Human genes 0.000 description 6
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 6
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 101100501302 Staphylococcus aureus emp gene Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000005006 adaptive immune system Anatomy 0.000 description 6
- 239000013566 allergen Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000001155 isoelectric focusing Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 5
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000005784 autoimmunity Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 231100000776 exotoxin Toxicity 0.000 description 5
- 239000002095 exotoxin Substances 0.000 description 5
- 210000000224 granular leucocyte Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 229960003130 interferon gamma Drugs 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 4
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 102000003939 Membrane transport proteins Human genes 0.000 description 4
- 108090000301 Membrane transport proteins Proteins 0.000 description 4
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 101710102803 Tumor suppressor ARF Proteins 0.000 description 4
- 101150042295 arfA gene Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 101150087557 omcB gene Proteins 0.000 description 4
- 101150115693 ompA gene Proteins 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 108010065152 Coagulase Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 101800001509 Large capsid protein Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 108090000988 Lysostaphin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 3
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108091003202 SecA Proteins Proteins 0.000 description 3
- 102000003673 Symporters Human genes 0.000 description 3
- 108090000088 Symporters Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 206010048038 Wound infection Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 101150103637 bkdB gene Proteins 0.000 description 3
- 101150049515 bla gene Proteins 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002283 elective surgery Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000008348 humoral response Effects 0.000 description 3
- 230000006054 immunological memory Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 101150028177 pdhB gene Proteins 0.000 description 3
- 101150086832 pdhC gene Proteins 0.000 description 3
- 206010034674 peritonitis Diseases 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940070376 protein Drugs 0.000 description 3
- 101150108007 prs gene Proteins 0.000 description 3
- 101150086435 prs1 gene Proteins 0.000 description 3
- 101150070305 prsA gene Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 231100000617 superantigen Toxicity 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- 108090000254 Aureolysin Proteins 0.000 description 2
- 101100330160 Bacillus subtilis (strain 168) cymR gene Proteins 0.000 description 2
- 101100376463 Bacillus subtilis (strain 168) yitU gene Proteins 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 101710198480 Clumping factor A Proteins 0.000 description 2
- 101710198481 Clumping factor B Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100035406 Cysteine desulfurase, mitochondrial Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101001023837 Homo sapiens Cysteine desulfurase, mitochondrial Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 101100463787 Pectobacterium carotovorum subsp. carotovorum peh gene Proteins 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 101150070497 accC gene Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000007622 bioinformatic analysis Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 102000014509 cathelicidin Human genes 0.000 description 2
- 108060001132 cathelicidin Proteins 0.000 description 2
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000004695 complexes Chemical class 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- VLYUGYAKYZETRF-UHFFFAOYSA-N dihydrolipoamide Chemical compound NC(=O)CCCCC(S)CCS VLYUGYAKYZETRF-UHFFFAOYSA-N 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 108010064033 elastin-binding proteins Proteins 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 102000033737 extracellular matrix binding proteins Human genes 0.000 description 2
- 108091009712 extracellular matrix binding proteins Proteins 0.000 description 2
- 101150090981 fabG gene Proteins 0.000 description 2
- 102000036072 fibronectin binding proteins Human genes 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 101150068528 mabA gene Proteins 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940037645 staphylococcus epidermidis Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- RNQVGVKGGAODSC-MEXJFSEESA-N 1-[(3R,4R,5R,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]ethanone Chemical compound C(C)(=O)[C@]1([C@H](C(O)O[C@@H]([C@H]1O)CO)N)O RNQVGVKGGAODSC-MEXJFSEESA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical compound COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 1
- YQNRVGJCPCNMKT-JLPGSUDCSA-N 2-(4-benzylpiperazin-1-yl)-n-[(2-hydroxy-3-prop-2-enyl-phenyl)methylideneamino]acetamide Chemical compound OC1=C(CC=C)C=CC=C1\C=N/NC(=O)CN1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-JLPGSUDCSA-N 0.000 description 1
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 101710138614 3-oxoacyl-[acyl-carrier-protein] reductase Proteins 0.000 description 1
- 101710095299 3-oxoacyl-[acyl-carrier-protein] reductase FabG Proteins 0.000 description 1
- 101710173786 3-oxoacyl-[acyl-carrier-protein] reductase MabA Proteins 0.000 description 1
- 101710136750 3-oxoacyl-[acyl-carrier-protein] reductase, chloroplastic Proteins 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102100035841 60S ribosomal protein L7 Human genes 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 102100040190 ADP-ribosylation factor-binding protein GGA2 Human genes 0.000 description 1
- 101100059051 Acidianus filamentous virus 1 (isolate United States/Yellowstone) ORF132 gene Proteins 0.000 description 1
- 101100050731 Acidianus filamentous virus 2 (isolate Italy/Pozzuoli) ORF178 gene Proteins 0.000 description 1
- 101100374232 Acidianus filamentous virus 2 (isolate Italy/Pozzuoli) ORF202 gene Proteins 0.000 description 1
- 101100265191 Acidianus filamentous virus 2 (isolate Italy/Pozzuoli) ORF208 gene Proteins 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 206010059837 Adhesion Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 244000109331 Albuca major Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 102000003669 Antiporters Human genes 0.000 description 1
- 108090000084 Antiporters Proteins 0.000 description 1
- 101000956748 Arabidopsis thaliana Uncharacterized mitochondrial protein AtMg00050 Proteins 0.000 description 1
- 101001036640 Arabidopsis thaliana Uncharacterized mitochondrial protein AtMg00820 Proteins 0.000 description 1
- 101000956719 Arabidopsis thaliana Uncharacterized mitochondrial protein AtMg01090 Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000244185 Ascaris lumbricoides Species 0.000 description 1
- 101100214862 Autographa californica nuclear polyhedrosis virus AC152 gene Proteins 0.000 description 1
- 101100214860 Autographa californica nuclear polyhedrosis virus Ac132 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100269722 Bacillus subtilis (strain 168) alsT gene Proteins 0.000 description 1
- 101100507429 Bacillus subtilis (strain 168) hxlA gene Proteins 0.000 description 1
- 101100289920 Bacillus subtilis (strain 168) lytD gene Proteins 0.000 description 1
- 101100311413 Bacillus subtilis (strain 168) sufD gene Proteins 0.000 description 1
- 101100213134 Bacillus subtilis (strain 168) ydaP gene Proteins 0.000 description 1
- 101100432201 Bacillus subtilis (strain 168) yhjN gene Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 101000742291 Bifidobacterium adolescentis (strain ATCC 15703 / DSM 20083 / NCTC 11814 / E194a) Reducing end xylose-releasing exo-oligoxylanase Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032840 Catheter-Related Infections Diseases 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 101000792445 Chlorella vulgaris Uncharacterized 15.7 kDa protein in ycf4-trnK intergenic region Proteins 0.000 description 1
- 101000748765 Chlorella vulgaris Uncharacterized 16.5 kDa protein in psaC-atpA intergenic region Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 101001014190 Dictyostelium discoideum Uncharacterized mitochondrial protein 21 Proteins 0.000 description 1
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 1
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 1
- 101100224495 Drosophila melanogaster Chrac-14 gene Proteins 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101100218573 Escherichia coli (strain K12) bcsB gene Proteins 0.000 description 1
- 101100126177 Escherichia coli (strain K12) intR gene Proteins 0.000 description 1
- 101100136641 Escherichia coli (strain K12) pifC gene Proteins 0.000 description 1
- 101100376706 Escherichia coli (strain K12) ymiA gene Proteins 0.000 description 1
- 101000792454 Euglena gracilis Uncharacterized 32.3 kDa protein in rbcL-atpE intergenic region Proteins 0.000 description 1
- 101000792447 Euglena gracilis Uncharacterized 35.4 kDa protein in rbcL-atpE intergenic region Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 101710128530 Fibrinogen-binding protein Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 101001076781 Fructilactobacillus sanfranciscensis (strain ATCC 27651 / DSM 20451 / JCM 5668 / CCUG 30143 / KCTC 3205 / NCIMB 702811 / NRRL B-3934 / L-12) Ribose-5-phosphate isomerase A Proteins 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000853617 Homo sapiens 60S ribosomal protein L7 Proteins 0.000 description 1
- 101001037082 Homo sapiens ADP-ribosylation factor-binding protein GGA2 Proteins 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 101001139126 Homo sapiens Krueppel-like factor 6 Proteins 0.000 description 1
- 101001133600 Homo sapiens Pituitary adenylate cyclase-activating polypeptide type I receptor Proteins 0.000 description 1
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 1
- 101001104570 Homo sapiens Proteasome assembly chaperone 2 Proteins 0.000 description 1
- 101001104566 Homo sapiens Proteasome assembly chaperone 3 Proteins 0.000 description 1
- 101000625842 Homo sapiens Tubulin-specific chaperone E Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 101710172804 K protein Proteins 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 102100020679 Krueppel-like factor 6 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 101000916361 Leptolyngbya boryana Uncharacterized 14.6 kDa protein in sodA1 3'region Proteins 0.000 description 1
- 108010014603 Leukocidins Proteins 0.000 description 1
- 101710177649 Low affinity immunoglobulin gamma Fc region receptor III Proteins 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000008826 LysM domains Human genes 0.000 description 1
- 108050000721 LysM domains Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100038261 Methanococcus vannielii (strain ATCC 35089 / DSM 1224 / JCM 13029 / OCM 148 / SB) rpo2C gene Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 108091078963 MmpL family Proteins 0.000 description 1
- 102000005455 Monosaccharide Transport Proteins Human genes 0.000 description 1
- 108010006769 Monosaccharide Transport Proteins Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101001007347 Mycoplasma hominis (strain ATCC 23114 / NBRC 14850 / NCTC 10111 / PG21) Protein LemA Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 101100426292 Myxococcus xanthus (strain DK1622) trmFO gene Proteins 0.000 description 1
- 108090000836 Nitrate Transporters Proteins 0.000 description 1
- 101150083029 ORF147 gene Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 101100028042 Orgyia pseudotsugata multicapsid polyhedrosis virus OPEP-3 gene Proteins 0.000 description 1
- 101100083931 Orgyia pseudotsugata multicapsid polyhedrosis virus P26 gene Proteins 0.000 description 1
- 101100463342 Orgyia pseudotsugata multicapsid polyhedrosis virus PE38 gene Proteins 0.000 description 1
- 101000783504 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 15.4 kDa protein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229960005552 PAC-1 Drugs 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001307210 Pene Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101100274323 Pinus contorta chlN gene Proteins 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100041008 Proteasome assembly chaperone 2 Human genes 0.000 description 1
- 102100041010 Proteasome assembly chaperone 3 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101150071963 RBSK gene Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 101000827751 Rhodobacter capsulatus Uncharacterized 30.4 kDa protein in puhA 5'region Proteins 0.000 description 1
- 102100020783 Ribokinase Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101150054830 S100A6 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 101000817083 Salmonella phage P22 Uncharacterized 22.8 kDa protein in gp15-gp3 intergenic region Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010058028 Shunt infection Diseases 0.000 description 1
- 101100301564 Staphylococcus aureus repF gene Proteins 0.000 description 1
- 101100280885 Staphylococcus haemolyticus (strain JCSC1435) femX gene Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 101000768322 Synechococcus sp. (strain WH8020) Uncharacterized 16.1 kDa protein in cpeY 3'region Proteins 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000251221 Triakidae Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 108010076595 adenosylhomocysteine nucleosidase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 238000002819 bacterial display Methods 0.000 description 1
- 101150099720 basR gene Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 101150027005 divIB gene Proteins 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 108010024615 duroquinol oxidase Proteins 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 102000025748 fibrinogen binding proteins Human genes 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 101150077522 hemN gene Proteins 0.000 description 1
- 101150053787 hemW gene Proteins 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 108010025743 hexose phosphate synthetase Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229940029583 inactivated polio vaccine Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 101150034648 mnmG gene Proteins 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 229940127241 oral polio vaccine Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 101150069659 pmrA gene Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- XIBUKSQTWSKJMQ-QTNFYWBSSA-M potassium;(4s)-4-amino-5-hydroxy-5-oxopentanoate;hydrate Chemical compound O.[K+].[O-]C(=O)[C@@H](N)CCC(O)=O XIBUKSQTWSKJMQ-QTNFYWBSSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 101150043558 repc gene Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 101150085857 rpo2 gene Proteins 0.000 description 1
- 101150090202 rpoB gene Proteins 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 101150064504 sdrC gene Proteins 0.000 description 1
- 101150073644 sdrE gene Proteins 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 108010051423 streptavidin-agarose Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000004441 taeniasis Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 108010042582 tosylarginine methyl ester hydrolase Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Computational Biology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0013001A AT410798B (de) | 2001-01-26 | 2001-01-26 | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200305764B true ZA200305764B (en) | 2004-07-26 |
Family
ID=3636418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200305764A ZA200305764B (en) | 2001-01-26 | 2003-07-25 | A method for identification, isolation and production of antigens to a specific pathogen. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US7968297B2 (fr) |
| EP (6) | EP2322539A3 (fr) |
| JP (2) | JP2004531476A (fr) |
| KR (4) | KR100851728B1 (fr) |
| CN (2) | CN1649894A (fr) |
| AT (2) | AT410798B (fr) |
| AU (3) | AU2002247641B8 (fr) |
| BR (1) | BR0207067A (fr) |
| CA (2) | CA2436057C (fr) |
| CZ (1) | CZ20032201A3 (fr) |
| DE (1) | DE60207194T2 (fr) |
| DK (1) | DK1355930T3 (fr) |
| ES (1) | ES2252438T3 (fr) |
| HU (1) | HUP0402048A3 (fr) |
| IL (4) | IL157082A0 (fr) |
| IS (1) | IS6895A (fr) |
| MX (1) | MXPA03006702A (fr) |
| NO (1) | NO20033364L (fr) |
| NZ (4) | NZ551802A (fr) |
| PL (2) | PL214482B1 (fr) |
| RU (1) | RU2289817C2 (fr) |
| SK (1) | SK10492003A3 (fr) |
| WO (1) | WO2002059148A2 (fr) |
| ZA (1) | ZA200305764B (fr) |
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2708949C (fr) | 2001-01-03 | 2016-03-08 | Epitopix Llc. | Compositions immunisantes et leurs procedes d'utilisation |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| MXPA03011701A (es) | 2001-06-15 | 2004-12-06 | Nhibitex Inc | Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus. |
| GB0200865D0 (en) * | 2002-01-16 | 2002-03-06 | Univ Bristol | Method |
| GB2387600A (en) * | 2002-04-19 | 2003-10-22 | Pantherix Ltd | Pantothenate kinase |
| CA2484335A1 (fr) * | 2002-10-03 | 2004-04-15 | Intercell Ag | Utilisation de molecules qui interagissent avec la liaison aux ligands du recepteur de l'haptoglobine |
| EP2287311A1 (fr) * | 2003-03-04 | 2011-02-23 | Intercell AG | Antigènes pyogènes streptococcus |
| CA2520868A1 (fr) | 2003-03-31 | 2004-10-14 | Intercell Ag | Antigenes s. epidermidis |
| EP2311991A1 (fr) | 2003-04-15 | 2011-04-20 | Intercell AG | S. pneumoniae antigènes |
| US20060193866A1 (en) * | 2003-04-22 | 2006-08-31 | Intercell Ag | H pylori antigens |
| EP2289907A3 (fr) * | 2003-05-07 | 2011-08-31 | Intercell AG | Antigènes I + II de Streptococcus agalactiae |
| EP2327720A1 (fr) * | 2003-05-30 | 2011-06-01 | Intercell AG | Antigènes d'entérocoque |
| US20060188515A1 (en) * | 2003-07-24 | 2006-08-24 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| NZ570750A (en) * | 2003-07-24 | 2009-12-24 | Merck & Co Inc | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| ES2395022T3 (es) | 2003-09-19 | 2013-02-07 | Epitopix, Llc | Polipéptidos de Campylobacter y sus métodos de uso |
| US20070134263A1 (en) * | 2004-02-18 | 2007-06-14 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphyloococcus aureus |
| WO2005086663A2 (fr) * | 2004-02-27 | 2005-09-22 | Merck & Co., Inc. | Polypeptides destines a induire une reponse immunitaire de protection contre le staphylococcus aureus |
| JP2005278537A (ja) * | 2004-03-30 | 2005-10-13 | Dai Ichi Seiyaku Co Ltd | 新規ポリペプチド |
| JP2008508855A (ja) * | 2004-04-27 | 2008-03-27 | インターツェル・アクチェンゲゼルシャフト | Ｔｄ抗原 |
| WO2006065272A2 (fr) | 2004-05-21 | 2006-06-22 | Idaho Research Foundation, Inc. | Procedes permettant de modifier la production d'acide acetique et de favoriser la mort cellulaire chez les bacteries |
| US20070243205A1 (en) * | 2004-05-25 | 2007-10-18 | Anderson Annaliesa S | Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus |
| EP1781326A4 (fr) * | 2004-06-04 | 2009-01-14 | Pharmexa Inc | Induction d'une reponse immunitaire contre des polysaccharides streptococcus pneumoniae |
| FR2871237B1 (fr) * | 2004-06-08 | 2011-03-11 | Abag | Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes |
| FR2871159A1 (fr) * | 2004-06-08 | 2005-12-09 | Abag Sa | Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative |
| WO2007018482A2 (fr) * | 2004-07-06 | 2007-02-15 | Merck & Co., Inc. | Polypeptides utilises pour induire une reponse immunitaire protectrice contre le staphylococcus aureus |
| EP1791560A4 (fr) * | 2004-09-17 | 2009-01-14 | Merck & Co Inc | Polypeptides pour induire une reponse immunitaire de protection dirigee contre staphylococcus aureus |
| KR101359930B1 (ko) | 2004-09-22 | 2014-02-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성조성물 |
| AU2005333603A1 (en) | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens |
| CA2583026A1 (fr) * | 2004-10-29 | 2006-05-04 | Intercell Ag | Vaccins anti-vhc pour patients atteints du vhc chronique |
| AU2006206577B2 (en) | 2005-01-21 | 2012-03-08 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against Staphylococcus aureus |
| DK1848732T3 (en) | 2005-01-21 | 2016-11-14 | Epitopix Llc | YERSINIA SPP.-POLYPEPTIDES AND METHODS OF USE |
| NZ589238A (en) | 2005-02-14 | 2012-02-24 | Epitopix Llc | Polypeptides from staphylococcus aureus and methods of use |
| CA2602615A1 (fr) * | 2005-04-04 | 2006-10-12 | Viventia Biotech Inc. | Procede et systeme pour l'identification d'antigene |
| WO2006121664A2 (fr) * | 2005-05-05 | 2006-11-16 | Merck & Co., Inc. | Polypeptides induisant une reponse immunitaire de protection contre staphylococcus aureus |
| WO2006124644A2 (fr) * | 2005-05-12 | 2006-11-23 | Board Of Regents, The University Of Texas System | Etablissement de profils de proteines et d'anticorps au moyen de microreseaux de petites molecules |
| BRPI0613026A2 (pt) * | 2005-07-14 | 2012-01-03 | Bharat Biotech Int Ltd | composiÇço, fragmento de nucleotÍdeo, constructo de dna recombinante, mÉtodo para produzir proteÍna, composiÇço farmacÊutica e mÉtodo para uso da mesma, formulaÇço, mÉtodo de administrar composiÇço farmacÊutica, mÉtodo de prevenÇço e controle de infecÇÕes associadas a staphylococcus |
| AU2007281934B2 (en) * | 2006-01-18 | 2012-11-15 | University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| SG170090A1 (en) | 2006-03-30 | 2011-04-29 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0610776D0 (en) * | 2006-05-31 | 2006-07-12 | Univ Bath | Novel applications for staphylococcus aureus Sbi protein |
| EP2289906A1 (fr) * | 2006-09-15 | 2011-03-02 | Intercell AG | Antigènes de la Borrelia |
| US20080102067A1 (en) * | 2006-10-25 | 2008-05-01 | Cook Mark E | Immunogenic composition |
| EP1923069A1 (fr) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protecteurs contre S. pneumoniae et compositions, méthodes et utilisations associés |
| EP1935984A1 (fr) * | 2006-12-20 | 2008-06-25 | Unilever N.V. | Procédé d'assistance à la conduite et appareil d'assistance à la conduite |
| WO2008140632A2 (fr) | 2007-01-24 | 2008-11-20 | Merck & Co., Inc. | Polypeptides pour induire une réponse immunitaire protectrice contre staphylococcus epidermidis |
| CA2681035A1 (fr) * | 2007-03-19 | 2008-09-25 | Merck & Co., Inc. | Polypeptides pour induire une reponse immune protectrice contre staphylococcus epidermidis |
| US20100203075A1 (en) * | 2007-06-18 | 2010-08-12 | Intercell Ag | Chlamydia antigens |
| JP5658564B2 (ja) | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| BRPI0816506A2 (pt) * | 2007-10-18 | 2014-10-14 | Unilever Nv | "método para produzir um agente espumante" |
| CN101458255B (zh) * | 2007-12-14 | 2013-03-06 | 武汉大学 | 丙型肝炎病毒包膜抗原夹心法试剂盒及检测方法 |
| US20090196852A1 (en) * | 2008-02-04 | 2009-08-06 | Watkinson D Tobin | Compositions and methods for diagnosing and treating immune disorders |
| NZ588191A (en) | 2008-03-03 | 2012-06-29 | Irm Llc | Compounds and compositions as tlr activity modulators |
| JP2011514167A (ja) | 2008-03-17 | 2011-05-06 | インターセル アーゲー | 肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用 |
| WO2009158682A2 (fr) * | 2008-06-27 | 2009-12-30 | Watkinson D Tobin | Compositions et procédés pour diagnostiquer et traiter des troubles pathogènes |
| US20100015171A1 (en) * | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
| US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| CA2738793A1 (fr) * | 2008-09-30 | 2010-04-08 | University Of Maryland, Baltimore | Vaccin protecteur contre des biofilms de staphylococcus aureus renfermant des immunogenes associes a la paroi cellulaire |
| BRPI0920041A2 (pt) * | 2008-10-06 | 2017-06-27 | Univ Chicago | composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas |
| AU2009304092B2 (en) * | 2008-10-16 | 2013-09-05 | Unilever Plc | Hydrophobin solution containing antifoam |
| CA2744323A1 (fr) | 2008-11-26 | 2010-06-03 | Merck Sharp & Dohme Corp. | Polypeptides pour induire une reponse immunitaire de protection contre le staphylocoque dore |
| EP2376111A4 (fr) | 2008-11-26 | 2013-01-09 | Merck Sharp & Dohme | Polypeptides pour induire une réponse immunitaire protectrice contre staphylococcus aureus |
| SG162687A1 (en) | 2008-12-24 | 2010-07-29 | Millipore Corp | Caustic stable chromatography ligands |
| WO2010089340A2 (fr) | 2009-02-05 | 2010-08-12 | Intercell Ag | Peptides protecteurs contre e. faecalis, procédés et utilisations liés à ceux-ci |
| BRPI1011856A2 (pt) * | 2009-03-23 | 2020-11-03 | Epitopix, Llc | polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso |
| BRPI1010307B1 (pt) * | 2009-04-03 | 2021-07-27 | University Of Chicago | Polipeptídeos variantes de proteína a (spa), composição imunogênica compreendendo os mesmos, vacina, método de produção da referida vacina, bem como uso dos referidos polipeptídeos |
| NZ612315A (en) * | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| CA2704702C (fr) * | 2009-06-02 | 2018-06-12 | Unilever Plc | Produits aeres cuits au four |
| WO2010144734A1 (fr) | 2009-06-10 | 2010-12-16 | Novartis Ag | Vaccins contenant de la benzonaphtyridine |
| CA2766629C (fr) | 2009-06-22 | 2020-03-24 | Wyeth Llc | Compositions immunogenes d'antigenes de staphylococcus aureus |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| WO2011057148A1 (fr) | 2009-11-05 | 2011-05-12 | Irm Llc | Composés et compositions permettant de moduler l'activité des tlr-7 |
| CN102762206A (zh) | 2009-12-15 | 2012-10-31 | 诺华有限公司 | 免疫增强化合物的均匀悬液及其用途 |
| US8765148B2 (en) | 2010-02-19 | 2014-07-01 | Valneva Austria Gmbh | 1C31 nanoparticles |
| EA023725B1 (ru) | 2010-03-23 | 2016-07-29 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| JP2013523818A (ja) | 2010-04-05 | 2013-06-17 | ザ・ユニバーシティー・オブ・シカゴ | 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法 |
| BR112012029521A2 (pt) * | 2010-05-05 | 2018-03-06 | New York University | leucocidinas do staphylococcus aureus, composições terapêuticas, e aplicações das mesmas. |
| ES2655701T3 (es) | 2010-07-02 | 2018-02-21 | The University Of Chicago | Composiciones y métodos relacionados con variantes de la proteína A (SpA) |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| US8747858B2 (en) | 2010-07-13 | 2014-06-10 | Merck Sharp & Dohme Corp. | Staphylococcus aureus surface protein SA1789 and protective vaccine based thereon |
| US9095540B2 (en) | 2010-09-09 | 2015-08-04 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
| WO2012065034A1 (fr) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Vaccins à base de conjugués de peptide énolase, contre staphylococcus aureus |
| CN102558316B (zh) * | 2010-12-30 | 2015-07-01 | 上海雅心生物技术有限公司 | 高稳定性的具抗体结合能力的重组蛋白a及其生产 |
| US8945588B2 (en) * | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| MX340446B (es) | 2011-06-19 | 2016-07-08 | Univ New York | Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas. |
| KR20140071318A (ko) | 2011-06-19 | 2014-06-11 | 뉴욕 유니버시티 | 새로운 항-염증제 및 살균제로서의 류코톡신 e/d |
| WO2013066731A2 (fr) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Vaccin prophylactique à base de la protéine sa2451 de staphylococcus aureus |
| PL2817329T3 (pl) | 2012-02-20 | 2019-07-31 | Swedish Orphan Biovitrum Ab (Publ) | Polipeptydy wiążące z c5 ludzkiego dopełniacza |
| CN104768572B (zh) | 2012-04-26 | 2021-08-24 | 芝加哥大学 | 葡萄球菌凝固酶抗原及其使用方法 |
| EP2872173A4 (fr) | 2012-07-10 | 2016-03-23 | Merck Sharp & Dohme | Vaccin protecteur à base de protéine sa2493 de staphylococcus aureus |
| RU2526497C2 (ru) * | 2012-10-31 | 2014-08-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохарнения и социального развития Российской Федерации | Способ определения генотипов золотистого стафилококка |
| SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
| EP2935324B1 (fr) * | 2012-12-20 | 2019-10-23 | MorphoSys AG | Anticorps anti-staphylococciques |
| CN103965336B (zh) * | 2013-01-29 | 2016-08-10 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| BR112015018014A2 (pt) | 2013-02-01 | 2017-07-11 | Glaxosmithkline Biologicals Sa | liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll |
| WO2014175690A1 (fr) * | 2013-04-25 | 2014-10-30 | (재) 스크립스코리아 항체연구원 | Procédé pour raffiner une protéine comprenant une cassette à auto-coupure et son utilisation |
| JP7138411B2 (ja) | 2013-08-28 | 2022-09-16 | アフィボディ・アーベー | 変異した骨格を有する結合ポリペプチド |
| NZ718153A (en) * | 2013-08-28 | 2022-05-27 | Ipc Res Llc | Stable polypeptides binding to human complement c5 |
| CN104558196A (zh) * | 2013-10-15 | 2015-04-29 | 温州医科大学 | 基于HBcAg载体的沙眼衣原体主要外膜蛋白表位疫苗及其用途 |
| RU2542396C1 (ru) * | 2013-11-06 | 2015-02-20 | Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ и набор для ускоренной лабораторной диагностики коклюшной инфекции |
| WO2015082536A1 (fr) * | 2013-12-03 | 2015-06-11 | Evaxion Biotech Aps | Protéines et acides nucléiques utiles dans des vaccins ciblant staphylococcus aureus |
| CN103694323B (zh) * | 2013-12-09 | 2017-01-18 | 成都欧林生物科技股份有限公司 | 金黄色葡萄球菌MntC重组蛋白及其制备方法和应用 |
| US10100093B2 (en) | 2013-12-31 | 2018-10-16 | Epitopix Llc | Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use |
| WO2016000022A1 (fr) * | 2014-06-30 | 2016-01-07 | Murdoch Childrens Research Institute | Agent thérapeutique helicobacter |
| CN104569386B (zh) * | 2014-12-10 | 2016-05-11 | 中国水产科学研究院淡水渔业研究中心 | 一种罗非鱼源无乳链球菌elisa快速检测试剂盒及其检测方法 |
| WO2016096787A1 (fr) | 2014-12-17 | 2016-06-23 | F. Hoffmann-La Roche Ag | Réaction monotope enzymatique pour la double conjugaison de polypeptides en une seule étape à l'aide d'une sortase |
| JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
| CN108026560A (zh) | 2015-09-25 | 2018-05-11 | 豪夫迈·罗氏有限公司 | 在低共熔溶剂中使用分选酶的转酰胺反应 |
| WO2017050866A1 (fr) | 2015-09-25 | 2017-03-30 | F. Hoffmann-La Roche Ag | Nouvelle sortase a soluble |
| JP6895953B2 (ja) | 2015-09-25 | 2021-06-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ソルターゼａを利用してチオエステルを作製するための方法 |
| AU2016359722B2 (en) | 2015-11-27 | 2020-09-17 | Enantis S.R.O. | Thermostable FGF2 polypeptide, use thereof |
| US10166280B2 (en) | 2016-06-08 | 2019-01-01 | Epitopix, Llc | Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| US10504742B2 (en) * | 2017-05-31 | 2019-12-10 | Asm Ip Holding B.V. | Method of atomic layer etching using hydrogen plasma |
| WO2018237010A2 (fr) * | 2017-06-20 | 2018-12-27 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions vaccinales contre streptococcus et leurs méthodes d'utilisation |
| CN111867623B (zh) | 2018-02-12 | 2024-06-04 | 英尼穆内公司 | Toll样受体配体 |
| US10905738B2 (en) | 2018-07-05 | 2021-02-02 | Biozeus Desenvolvimento De Produtos Biofarmacêuticos | Synthetic peptides, prodrugs, pharmaceutical compositions and uses |
| RU2689161C1 (ru) * | 2018-10-04 | 2019-05-24 | Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ получения бактериальных антигенов |
| CN111110838A (zh) * | 2019-12-24 | 2020-05-08 | 华南师范大学 | 一种罗非鱼无乳链球菌疫苗及其制备方法 |
| CN111808977B (zh) * | 2020-07-23 | 2023-06-27 | 清华大学深圳国际研究生院 | 一种由snp所引起利福平类抗生素耐药的抗性基因的特异性引物的设计方法及检测方法 |
| WO2022096596A1 (fr) | 2020-11-04 | 2022-05-12 | Eligo Bioscience | Phages recombinants de cutibacterium acnes, leur procédé de production et leurs utilisations |
| KR102281369B1 (ko) * | 2021-04-07 | 2021-07-22 | 씨제이제일제당 (주) | 신규한 디히드로리포일 아세틸기전이효소 변이체 및 이를 이용한 l-발린 생산 방법 |
| KR102306010B1 (ko) * | 2021-04-07 | 2021-09-27 | 씨제이제일제당 (주) | 신규한 분지쇄아미노산 투과효소 변이체 및 이를 이용한 l-발린 생산 방법 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU648251B2 (en) * | 1989-03-09 | 1994-04-21 | Wyeth Holdings Corporation | Vaccines for nontypable haemophilus influenzae |
| US5980908A (en) * | 1991-12-05 | 1999-11-09 | Alfa Laval Ab | Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment |
| US5456907A (en) | 1992-01-10 | 1995-10-10 | Helene Curtis, Inc. | Cysteamine permanent wave composition and method |
| EP0857214A1 (fr) * | 1995-10-16 | 1998-08-12 | Smithkline Beecham Plc | Nouvelle proteine fixant la salive |
| US6737248B2 (en) * | 1996-01-05 | 2004-05-18 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| CO4600681A1 (es) | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
| US6380370B1 (en) * | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| EP1036321A1 (fr) * | 1997-12-05 | 2000-09-20 | Intercell Biomedizinische Forschungs- und Entwicklungs GmbH | Technique de cellules pour criblage de bibliotheques combinatoires |
| DE19803453A1 (de) | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
| JP2002513589A (ja) * | 1998-04-30 | 2002-05-14 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 再アレー化を伴う、発現ライブラリーのクローンを選択するための新規方法 |
| WO1999067376A1 (fr) * | 1998-06-25 | 1999-12-29 | Institut Pasteur | Analyse exhaustive d'interactions de proteines virales au moyen d'un criblage a deux hybrides et selection de polypeptides a interaction virale correctement plies |
| US6610836B1 (en) * | 1999-01-29 | 2003-08-26 | Genome Therapeutics Corporation | Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics |
| AT407643B (de) * | 1999-02-01 | 2001-05-25 | Intercell Biomedizinische Forschungs & Entwicklungs Gmbh | Verfahren zur selektion und herstellung von vakzin- und diagnostika-präparationen |
| US6936258B1 (en) * | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| WO2000068373A1 (fr) * | 1999-05-05 | 2000-11-16 | Tvw Telethon Institute For Child Health Research | Isolation de modulateurs biologiques a partir de banques de fragments de genes presentant une diversite biologique |
| IL146544A0 (en) * | 1999-08-06 | 2002-07-25 | Ivigene Corp | Microbial polynucleotides expressed during infection of a host |
| AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| KR20020097200A (ko) | 2000-03-21 | 2002-12-31 | 엘리트라 파마슈티컬즈, 인코포레이티드 | 원핵세포에서의 필수유전자의 동정 |
| AU8181201A (en) | 2000-06-08 | 2001-12-17 | Cistem Biotechnologies Gmbh | Immunostimulatory oligodeoxynucleotides |
| GB0014907D0 (en) * | 2000-06-20 | 2000-08-09 | Univ Sheffield | Antigenic polypeptides |
| CA2418854A1 (fr) | 2000-08-17 | 2002-02-21 | Jorg Fritz | Vaccin comprenant au moins un antigene et un peptide antimicrobien a base de cathelicidine ou un derive de ce peptide |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| WO2002077183A2 (fr) | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification de genes essentiels dans des microorganismes |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| MXPA03011701A (es) | 2001-06-15 | 2004-12-06 | Nhibitex Inc | Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus. |
| WO2003011899A2 (fr) | 2001-08-02 | 2003-02-13 | University Of Sheffield | Polypeptides antigeniques |
| NZ570750A (en) | 2003-07-24 | 2009-12-24 | Merck & Co Inc | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| ATE410798T1 (de) | 2005-06-13 | 2008-10-15 | Research In Motion Ltd | Elektrischer verbinder und elektrisches system für ein bauteil in einem elektronischen gerät |
-
2001
- 2001-01-26 AT AT0013001A patent/AT410798B/de not_active IP Right Cessation
-
2002
- 2002-01-21 KR KR1020037009882A patent/KR100851728B1/ko not_active IP Right Cessation
- 2002-01-21 US US10/470,048 patent/US7968297B2/en not_active Expired - Fee Related
- 2002-01-21 IL IL15708202A patent/IL157082A0/xx unknown
- 2002-01-21 PL PL392964A patent/PL214482B1/pl unknown
- 2002-01-21 EP EP10178465A patent/EP2322539A3/fr not_active Withdrawn
- 2002-01-21 CN CNA028057651A patent/CN1649894A/zh active Pending
- 2002-01-21 KR KR1020097017433A patent/KR20090101973A/ko not_active Application Discontinuation
- 2002-01-21 CN CNA2008101610502A patent/CN101492496A/zh active Pending
- 2002-01-21 EP EP05108422A patent/EP1616876A3/fr not_active Withdrawn
- 2002-01-21 CZ CZ20032201A patent/CZ20032201A3/cs unknown
- 2002-01-21 DK DK02716669T patent/DK1355930T3/da active
- 2002-01-21 DE DE60207194T patent/DE60207194T2/de not_active Expired - Lifetime
- 2002-01-21 JP JP2002559450A patent/JP2004531476A/ja active Pending
- 2002-01-21 EP EP05024214.8A patent/EP1630172B1/fr not_active Expired - Lifetime
- 2002-01-21 CA CA2436057A patent/CA2436057C/fr not_active Expired - Fee Related
- 2002-01-21 NZ NZ551802A patent/NZ551802A/xx not_active IP Right Cessation
- 2002-01-21 HU HU0402048A patent/HUP0402048A3/hu unknown
- 2002-01-21 EP EP10178476A patent/EP2319861A1/fr not_active Withdrawn
- 2002-01-21 KR KR1020087006114A patent/KR100901915B1/ko not_active IP Right Cessation
- 2002-01-21 SK SK1049-2003A patent/SK10492003A3/sk unknown
- 2002-01-21 NZ NZ565349A patent/NZ565349A/en not_active IP Right Cessation
- 2002-01-21 NZ NZ527440A patent/NZ527440A/xx unknown
- 2002-01-21 AU AU2002247641A patent/AU2002247641B8/en not_active Ceased
- 2002-01-21 RU RU2003125967/13A patent/RU2289817C2/ru not_active IP Right Cessation
- 2002-01-21 NZ NZ540764A patent/NZ540764A/en not_active IP Right Cessation
- 2002-01-21 BR BR0207067-7A patent/BR0207067A/pt not_active IP Right Cessation
- 2002-01-21 EP EP10178468A patent/EP2412722A1/fr not_active Withdrawn
- 2002-01-21 KR KR1020087026439A patent/KR20080107477A/ko not_active Application Discontinuation
- 2002-01-21 MX MXPA03006702A patent/MXPA03006702A/es active IP Right Grant
- 2002-01-21 EP EP02716669A patent/EP1355930B1/fr not_active Expired - Lifetime
- 2002-01-21 WO PCT/EP2002/000546 patent/WO2002059148A2/fr active Application Filing
- 2002-01-21 ES ES02716669T patent/ES2252438T3/es not_active Expired - Lifetime
- 2002-01-21 AT AT02716669T patent/ATE309268T1/de active
- 2002-01-21 CA CA2792244A patent/CA2792244A1/fr not_active Abandoned
- 2002-01-21 PL PL367125A patent/PL209115B1/pl unknown
-
2003
- 2003-07-25 IS IS6895A patent/IS6895A/is unknown
- 2003-07-25 NO NO20033364A patent/NO20033364L/no not_active Application Discontinuation
- 2003-07-25 ZA ZA200305764A patent/ZA200305764B/en unknown
-
2006
- 2006-12-21 US US11/614,716 patent/US7771728B2/en not_active Expired - Fee Related
-
2007
- 2007-10-17 IL IL186706A patent/IL186706A/en not_active IP Right Cessation
- 2007-11-16 AU AU2007234519A patent/AU2007234519B2/en not_active Ceased
-
2008
- 2008-06-11 JP JP2008152742A patent/JP5053933B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-12 AU AU2010200549A patent/AU2010200549A1/en not_active Abandoned
- 2010-08-09 US US12/853,074 patent/US8323660B2/en not_active Expired - Fee Related
-
2011
- 2011-02-03 IL IL211038A patent/IL211038A0/en unknown
- 2011-02-03 IL IL211037A patent/IL211037A/en not_active IP Right Cessation
-
2012
- 2012-09-13 US US13/613,761 patent/US8715688B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8715688B2 (en) | Method for identification, isolation and production of antigens to a specific pathogen | |
| AU2002247641A1 (en) | A method for identification, isolation and production of antigens to a specific pathogen | |
| JP2004531476A5 (fr) | ||
| AU2006249236B2 (en) | A Method for Identification, Isolation and Production of Antigens to a Specific Pathogen | |
| MEINKE et al. | Patent 2436057 Summary |